WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) has announced an expansion of its savings programs for US patients requiring inhaled respiratory medications, including treatments for asthma and chronic obstructive pulmonary disease (COPD). Starting June 1, 2024, eligible patients will be able to obtain their inhalers for no more than $35 per month.
The initiative includes AstraZeneca's entire US inhaled respiratory portfolio, which features medications such as AIRSUPRA®, BEVESPI AEROSPHERE®, BREZTRI AEROSPHERE®, and SYMBICORT®. This move builds upon the company's commitment to improving access and affordability of critical medicines for patients who are uninsured or underinsured.
Pascal Soriot, CEO of AstraZeneca, emphasized that while the company is dedicated to making its medicines more affordable, the complexity of the healthcare system requires collaborative efforts for reform. He urged Congress to convene key stakeholders to ensure patients can afford their medications not only today but in the future as well.
The expansion of the savings program comes after AstraZeneca significantly reduced the list price of SYMBICORT on January 1, 2024, and pledged to continue providing discounts and rebates to facilitate patient access to its inhaled respiratory medicines.
AstraZeneca has a long history of serving respiratory patients, spanning over 50 years, with a focus on developing new drug-device combinations and novel treatments to meet the extensive unmet needs of chronic respiratory diseases.
The savings program is subject to terms and conditions, and federal government insurance program enrollees are excluded from co-pay support due to government restrictions.
This initiative is part of AstraZeneca's broader efforts to enhance patient care through its AZ&Me Prescription Savings Program, which has been providing assistance to patients for over four decades, helping over five million people since 2007. The program is designed to help those prescribed AstraZeneca medications who face financial barriers to accessing them.
The information for this article is based on a press release statement from AstraZeneca.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.